Oncolys BioPharma applies phase II clinical trial of OBP-301 in U.S

Wednesday, Aug 31, 2016

Oncolys BioPharma Inc Says it submitted clinical trial plan (protocol) to the United States Food and Drug Administration for phase II clinical trial of oncolytic virus OBP-301 (Telomelysin) in U.S.

Says unresectable or metastatic malignant melanoma is the target of the clinical trial.


Source :

Other News